KPI-121 0.25% Ophthalmic Suspension

DRUG3 trials

Sponsors

Kala Pharmaceuticals, Inc.

Conditions

Diabetic Macular EdemaDry Eye SyndromesKeratoconjunctivitis SiccaRetinal Vein Occlusion

Phase 3

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

CompletedNCT02813265

Kala Pharmaceuticals, Inc.Dry Eye Syndromes, Keratoconjunctivitis Sicca

Start: 2016-06-30End: 2017-10-31Updated: 2021-02-03

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

CompletedNCT02819284

Kala Pharmaceuticals, Inc.Dry Eye Syndromes, Keratoconjunctivitis Sicca

Start: 2016-06-30End: 2017-09-30Updated: 2021-01-05

Unknown Phase

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

CompletedNCT02245516

Kala Pharmaceuticals, Inc.Diabetic Macular Edema, Retinal Vein Occlusion

Start: 2014-07-31End: 2014-12-31Updated: 2020-12-10